Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 22, 2026

[Latest] Global Employer of Record EOR Market Size/Share Worth USD 15.89 Billion by 2035 at a 9.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

View original at globenewswire.com
[Latest] Global Employer of Record EOR Market Size/Share Worth USD 15.89 Billion by 2035 at a 9.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) Austin, TX, USA, Jan…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • North America holds the largest marketplace in the Employer of Record arena with a well-developed ecosystem, high remote work adoption, and emphasis on global expansion

    80% confidence
  • Asia Pacific is expanding at the fastest rate of growth in the Employer of Record market due to swift economic growth, flourishing technology and startup spaces, and growing cross-border talent requirements

    80% confidence
  • The demand for EOR has increased due to the rise in companies expanding internationally, the development of the gig economy, and the lack of talent in home markets caused by remote working trends

    80% confidence
  • The EOR market will grow at a compound annual growth rate (CAGR) of about 9.24% during the forecast period 2026 to 2035

    80% confidence
  • The global Employer of Record EOR Market size & share was valued at approximately USD 6.82 Billion in 2025 and is expected to reach USD 7.45 Billion in 2026 and USD 15.89 Billion by 2035

    80% confidence
  • Aggregator model EOR services are by far the most widespread in the Employer of Record market as of 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com